High-dose REGN4461 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 265 | 脂肪萎縮症 | 1 |
265. 脂肪萎縮症
臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04159415 (ClinicalTrials.gov) | January 7, 2020 | 7/11/2019 | Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy | A Randomized, Double-Blind, Placebo-Controlled Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy | Generalized Lipodystrophy | Drug: Placebo;Drug: Low-Dose REGN4461;Drug: High-dose REGN4461 | Regeneron Pharmaceuticals | NULL | Active, not recruiting | 12 Years | N/A | All | 16 | Phase 2 | United States;Peru;Russian Federation;Turkey |